| |
| |
|
| Insider
Information: |
Fuchs Henry J |
| Relationship: |
|
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
222,228 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$18,063,061 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
222,228 |
|
|
| Total
Value |
$18,063,061 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Onyx Pharmaceuticals Inc |
ONXX |
EVP & Chief Medical Of... |
2008-11-18 |
14,891 |
2006-05-15 |
0 |
Premium* |
|
|
Ardea Biosciences Inc |
RDEA |
Director |
2012-06-19 |
0 |
2007-12-05 |
0 |
Premium* |
|
|
Biomarin Pharmaceutical Inc |
BMRN |
President, Worldwide R&D |
2024-03-15 |
196,872 |
2009-03-02 |
0 |
Premium* |
|
|
Genomic Health Inc |
GHDX |
Director |
2019-11-08 |
0 |
2014-04-01 |
0 |
Premium* |
|
|
Mirati Therapeutics, Inc. |
MRTX |
|
2023-01-20 |
10,465 |
2020-01-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
294 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 12
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| GHDX |
Genomic Health Inc |
Director |
– • – |
2014-04-01 |
4 |
A |
$26.57 |
$9,990 |
D/D |
376 |
376 |
0 |
- |
|
| GHDX |
Genomic Health Inc |
Director |
– • – |
2017-01-01 |
4 |
A |
$29.39 |
$9,993 |
D/D |
340 |
4,291 |
0 |
- |
|
| GHDX |
Genomic Health Inc |
Director |
– • – |
2017-07-01 |
4 |
A |
$32.55 |
$9,993 |
D/D |
307 |
4,915 |
0 |
- |
|
| GHDX |
Genomic Health Inc |
Director |
– • – |
2016-01-01 |
4 |
A |
$35.20 |
$9,997 |
D/D |
284 |
2,841 |
0 |
- |
|
| RDEA |
Ardea Biosciences Inc |
Director |
– • – |
2010-03-10 |
4 |
OE |
$2.76 |
$11,040 |
D/D |
4,000 |
14,416 |
0 |
- |
|
| GHDX |
Genomic Health Inc |
Director |
– • – |
2019-10-01 |
4 |
A |
$67.28 |
$12,447 |
D/D |
185 |
7,833 |
0 |
- |
|
| GHDX |
Genomic Health Inc |
Director |
– • – |
2019-07-01 |
4 |
A |
$58.86 |
$12,478 |
D/D |
212 |
7,648 |
0 |
- |
|
| RDEA |
Ardea Biosciences Inc |
Director |
– • – |
2010-01-11 |
4 |
OE |
$2.76 |
$16,560 |
D/D |
6,000 |
16,416 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Medical Officer |
• – – |
2010-07-23 |
4 |
AS |
$20.00 |
$16,660 |
D/D |
(833) |
31,000 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Medical Officer |
• – – |
2010-06-02 |
4 |
AS |
$20.00 |
$16,680 |
D/D |
(834) |
31,000 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Medical Officer |
• – – |
2010-09-01 |
4 |
AS |
$20.88 |
$17,411 |
D/D |
(834) |
31,000 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Medical Officer |
• – – |
2010-08-02 |
4 |
AS |
$22.03 |
$18,352 |
D/D |
(833) |
31,000 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Medical Officer |
• – – |
2010-10-01 |
4 |
AS |
$22.30 |
$18,578 |
D/D |
(833) |
31,000 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Medical Officer |
• – – |
2010-04-30 |
4 |
A |
$13.23 |
$19,072 |
D/D |
1,442 |
21,442 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Medical Officer |
• – – |
2011-03-01 |
4 |
S |
$24.18 |
$20,167 |
D/D |
(834) |
31,000 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Medical Officer |
• – – |
2013-04-30 |
4 |
A |
$22.21 |
$20,340 |
D/D |
916 |
45,505 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Medical Officer |
• – – |
2010-10-29 |
4 |
A |
$13.23 |
$21,188 |
D/D |
1,602 |
32,602 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2023-04-28 |
4 |
A |
$66.88 |
$21,200 |
D/D |
317 |
176,504 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2020-04-30 |
4 |
A |
$62.59 |
$21,217 |
D/D |
339 |
102,995 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Medical Officer |
• – – |
2014-04-30 |
4 |
A |
$29.69 |
$21,228 |
D/D |
715 |
74,565 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2017-04-28 |
4 |
A |
$70.30 |
$21,232 |
D/D |
302 |
140,494 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Medical Officer |
• – – |
2012-04-30 |
4 |
A |
$19.35 |
$21,242 |
D/D |
1,098 |
30,018 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2018-04-30 |
4 |
A |
$68.78 |
$21,254 |
D/D |
309 |
157,101 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2019-04-30 |
4 |
A |
$68.78 |
$21,254 |
D/D |
309 |
124,845 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Medical Officer |
• – – |
2016-04-29 |
4 |
A |
$51.26 |
$21,275 |
D/D |
415 |
121,081 |
0 |
- |
|
294 Records found
|
|
Page 4 of 12 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
